Thank you to Madrigal for sponsoring this Medication Review Video Module!

In this GHAPP Medication Review Video Module, nurse practitioner Whitney Steinmetz discusses the clinical profile of Resmetirom, a thyroid hormone receptor beta agonist indicated for adults with metabolic-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. Whitney explores the mechanism of action, dosage recommendations, and the dual primary endpoint success of Resmetirom in clinical trials. She highlights key considerations, including drug interactions and common side effects such as nausea and diarrhea, and how they are generally well-tolerated over time. Learn more about Resmetirom's impact on liver health and patient care by visiting the GHAPP website or app.

Thank you to Madrigal for sponsoring the Medication Review Video Module.

In this GHAPP Medication Review video, Robin Soto, a board-certified nurse practitioner at UC San Diego Health Hepatology, explains the mechanism of action of Resmetirom, the first and only FDA-approved drug for the treatment of MASH in adults with mild to moderate fibrosis (F2-F3). Robin describes how Resmetirom, a liver-directed, thyroid hormone receptor beta agonist, targets liver fat accumulation, promoting fatty acid oxidation and improving cholesterol metabolism. She highlights its anti-inflammatory effects and ability to reduce liver fibrosis by selectively activating receptors in the liver, while minimizing systemic side effects. For more information, visit the GHAPP website and ACE app.

Thank you to Madrigal for sponsoring this FAQ Video Module.

In this GHAPP FAQ Video Module, Jonathan Yeh, a physician assistant at the Center for Liver Disease and Transplantation at Columbia University Irving Medical Center, discusses advancements in diagnosing and staging metabolic dysfunction-associated steatohepatitis (MASH). He explains the transition from traditional liver biopsy to non-invasive testing methods such as FibroScan and the Enhanced Liver Fibrosis (ELF) test for assessing fibrosis stages. Jonathan highlights the use of these methods, in combination with blood tests, to provide reliable staging of fibrosis in patients with MASH. For more information, visit the GHAPP website or ACE app.

Thank you to Madrigal for sponsoring this FAQ Video Module.

In this GHAPP FAQ Video Module, Corrie Berk, NP, Director of Hepatology and Transplant Outreach Programs at the Texas Liver Institute, shares insights on the consequences of untreated metabolic-associated steatohepatitis (MASH) and the importance of early intervention. She discusses how MASH can silently progress to liver failure, liver cancer, and increase cardiovascular risks. Corrie provides valuable strategies for advanced practice providers (APPs) to educate patients, focusing on simplifying complex information, promoting lifestyle changes, and emphasizing the benefits of early intervention. For more information on MASH, visit the GHAPP website or app.

Thank you to Madrigal for sponsoring this FAQ Video Module.

In this GHAPP FAQ Video Module, Corrie Berk, NP, Director of Hepatology and Transplant Outreach Programs at the Texas Liver Institute, explains the liver condition known as MASH, or metabolic dysfunction-associated steatohepatitis, which was previously referred to as NASH. She describes MASH as an inflammatory liver disease caused by excess fat buildup in the liver and its close connection to metabolic issues like obesity, type 2 diabetes, and dyslipidemia. Corrie also discusses the significance of the name change from NASH to MASH, highlighting the shift toward recognizing metabolic health as a key factor in managing the disease. For more information, visit the GHAPP website or app.

Thank you to Madrigal for sponsoring this Journal Club Video Module!

In this GHAPP Journal Club review, Lisa Richards, a board-certified family nurse practitioner specializing in hepatology at UC San Diego Health, presents pivotal research from a February 2024 New England Journal of Medicine publication. The phase 3 randomized controlled trial evaluated the efficacy of Resmineron, the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. Lisa discusses key findings from the study, including improvements in liver fibrosis and NASH resolution in patients treated with Resmineron compared to placebo. Join her for an in-depth look at this groundbreaking therapy and its impact on patient care.

Thank you to Madrigal for sponsoring this episode of GHAPPcast.

In this episode of GHAPPcast, nurse practitioners Patrick Horne and April Morris from discuss the complexities of identifying and managing patients with metabolic-associated steatohepatitis (MASH). They explore clinical approaches, including the use of bloodwork, family history, and advanced diagnostic tools such as FibroScan, to recognize patients at risk. Patrick and April emphasize the importance of lifestyle interventions like diet and exercise alongside new medical therapies, while also offering practical tips for clinicians on patient monitoring and treatment management. Tune in for valuable insights into managing MASH in clinical practice.

Thank you to Ardelyx for sponsoring this FAQ Video Module!

Kim Orleck, GHAPP member and a Physician Assistant at Atlanta Gastroenterology Associates. In this FAQ, Kim shares some of the best practices for accelerating the process of finding the right therapy for IBS-C patients. She emphasizes the importance of using a positive diagnostic strategy to confidently diagnose IBS-C, reducing unnecessary tests, financial strain, and the time to treatment. Kim also discusses the significance of setting appropriate timelines, involving patients in therapy decisions, and considering factors like dosing, side effects, and cost to optimize treatment outcomes. For more details, visit ghapp.org.